Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Collagenase injection for Peyronie's disease: randomized double-blind placebo-controlled dose-finding study
ChiCTR2500106740Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Jul 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of collagenase clostridium histolyticum in Peyronie's disease (4 arms), sponsored by Renji Hospital. Primary endpoints: Change in penile curvature at week 24 and Proportion of subjects not receiving further treatment due to sufficient efficacy. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Peyronie's disease
Beyond the preview
Go deeper on ChiCTR2500106740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106740.